Background Previous studies on neoadjuvant therapy for BRCA1-driven ovarian cancer (OC) demonstrated higher efficacy of mitomycin C plus cisplatin combination as compared to standard drug schemes. These data call for evaluation of the utility of this regimen for the treatment of recurrent BRCA1-associated OC. Methods The study included 12 BRCA1 germ-line mutation carriers, whose disease relapsed after one (n = 4) or two (n = 8) lines of chemotherapy. The patients received cisplatin 100 mg/m2 and mitomycin C 10 mg/m2, given every four weeks, for 6 (n = 10), 8 (n = 1) or 5 (n = 1) cycles. Retrospective data on conventional treatment of OC relapses in BRCA1 heterozygotes (n = 47) served as a control. Results Grade 3–4 toxicities were observed in 4/12 (33%) cases. There were 6 complete responses (CR), 4 partial responses (PR) and 2 instances of stable disease (SD). Comparison of patients receiving mitomycin C plus cisplatin (n = 4) or conventional therapy (n = 44) at first relapse demonstrated marginal improvement of the progression-free survival (PFS) (16.6 months vs. 10.2 months, P = .067). Use of mitomycin C plus cisplatin (n = 8) for the treatment of second relapse resulted in significant prolongation of PFS as compared to standard regimens (n = 31) (14.8 months vs. 4.8 months, P = .002). Conclusions Mitomycin C plus cisplatin shows promising activity in recurrent BRCA1-driven ovarian cancer.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Matulonis UA, Sood AK, Fallowfield L et al (2016) Ovarian cancer. Nat Rev Dis Primers 2:16061. https://doi.org/10.1038/nrdp.2016.61
Matulonis UA (2018) Management of newly diagnosed or recurrent ovarian cancer. Clin Adv Hematol Oncol 16(6):426–437
Lheureux S, Braunstein M, Oza AM (2019) Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin 69(4):280–304. https://doi.org/10.3322/caac.21559
Lheureux S, Gourley C, Vergote I et al (2019) Epithelial ovarian cancer. Lancet 393(10177):1240–1253. https://doi.org/10.1016/S0140-6736(18)32552-2
Marchetti C, De Leo R, Musella A et al (2018) BRCA mutation status to personalize management of recurrent ovarian cancer: A multicenter study. Ann Surg Oncol 25(12):3701–3708. https://doi.org/10.1245/s10434-018-6700-6
Gorodnova T, Sokolenko A, Ni V et al (2019) BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy. Int J Gynecol Cancer 29(4):779–786. https://doi.org/10.1136/ijgc-2018-000175
Gorodnova TV, Kotiv KB, Ivantsov AO et al (2018) Efficacy of neoadjuvant therapy with cisplatin plus mitomycin C in BRCA1-mutated ovarian cancer. Int J Gynecol Cancer 28(8):1498–1506. https://doi.org/10.1097/IGC.0000000000001352
Safra T, Rogowski O, Muggia FM (2014) The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer. Int J Gynecol Cancer 24(3):488–495. https://doi.org/10.1097/IGC.0000000000000086
Bookman MA, Tyczynski JE, Espirito JL et al (2017) Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer. Gynecol Oncol 146(1):58–63. https://doi.org/10.1016/j.ygyno.2017.04.011
Moiseyenko VM, Chubenko VA, Moiseyenko FV et al (2014) Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation. Med Oncol 31(10):199. https://doi.org/10.1007/s12032-014-0199-x
NCCN clinical practice guidelines in oncology, Version 1.2020, ovarian cancer. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed 1 Apr 2020
Lindemann K, Gao B, Mapagu C et al (2018) Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Gynecol Oncol 150(2):239–246. https://doi.org/10.1016/j.ygyno.2018.05.020
Alsop K, Fereday S, Meldrum C et al (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30(21):2654–2663. https://doi.org/10.1200/JCO.2011.39.8545
Sokolenko AP, Bizin IV, Preobrazhenskaya EV et al (2020) Molecular profiles of BRCA1-associated ovarian cancer treated by platinum-based therapy: Analysis of primary, residual and relapsed tumors. Int J Cancer 146(7):1879–1888. https://doi.org/10.1002/ijc.32776
We are cordially thankful to Ms. Sophie Leonard for the editing of this manuscript.
This work has been supported by the Russian Science Foundation [grant number 19-75-10062].
Conflict of interest
Tatyana V. Gorodnova, Anna P. Sokolenko, Sergey V. Kondratiev, Khristina B. Kotiv, Alexey M. Belyaev, Igor V. Berlev, and Evgeny N. Imyanitov declare that they have no conflicts of interest.
The study was approved by the local Ethics Committee. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.
All patients provided written informed consent.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
About this article
Cite this article
Gorodnova, T.V., Sokolenko, A.P., Kondratiev, S.V. et al. Mitomycin C plus cisplatin for systemic treatment of recurrent BRCA1-associated ovarian cancer. Invest New Drugs 38, 1872–1878 (2020). https://doi.org/10.1007/s10637-020-00965-8
- BRCA1 mutation
- Mitomycin C plus cisplatin
- Ovarian cancer